Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemias

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

Leukemia volume 22, pages 1539–1541 (2008)Cite this article

Abstract

In acute myeloid leukemia (AML) with complex aberrant karyotype, a loss of one TP53 allele is frequently observed. We analyzed the incidence of TP53 mutations and deletions in 107 AML with complex aberrant karyotype. In 50 of 57 cases showing a loss of one TP53 allele, a TP53 mutation was detected in the remaining allele. In addition, in 33 of 50 cases with two TP53 copies, a TP53 mutation was found. Therefore, the frequency of TP53 mutations in AML with complex aberrant karyotype was 78%. In a second step, we analyzed TP53 mutations in a cohort of AML comprising different cytogenetic subgroups. TP53 mutations were detected in 33 of 235 cases (14%). Coincidences with other molecular mutations were rare. We confirmed a high incidence of TP53 mutations in AML with a complex aberrant karyotype (29/42, 69%) and demonstrated that TP53 mutations are very rare in AML without a complex aberrant karyotype (4/193, 2.1%).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Vogelstein B, Lane D, Levine AJ . Surfing the p53 network. Nature 2000; 408: 307–310.

    Article  CAS  PubMed  Google Scholar 

  2. Fenaux P, Jonveaux P, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebvre MH et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991; 78: 1652–1657.

    CAS  PubMed  Google Scholar 

  3. Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Lai JL, Vanrumbeke M et al. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol 1992; 80: 178–183.

    Article  CAS  PubMed  Google Scholar 

  4. Preudhomme C, Fenaux P . The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. Br J Haematol 1997; 98: 502–511.

    Article  CAS  PubMed  Google Scholar 

  5. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589–3595.

    Article  CAS  PubMed  Google Scholar 

  6. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T . Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005; 43: 227–238.

    Article  CAS  PubMed  Google Scholar 

  7. Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, Dugas M et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: A detailed analysis of 125 cases using conventional chromosome analysis and Fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 2002; 35: 20–29.

    Article  PubMed  Google Scholar 

  8. ISCN. In: Mitelman F (ed). ISCN 1995, Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature. S. Karger: Basel, 1995, pp 1–110.

  9. Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106: 2854–2861.

    Article  CAS  PubMed  Google Scholar 

  10. Christiansen DH, Andersen MK, Pedersen-Bjergaard J . Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001; 19: 1405–1413.

    Article  CAS  PubMed  Google Scholar 

  11. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK . Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006; 20: 1943–1949.

    Article  CAS  PubMed  Google Scholar 

  12. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336.

    Article  CAS  PubMed  Google Scholar 

  13. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al., on behalf of the Medical Research Council Addult and Children's Leukemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  14. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al., on behalf of the Medical Research Council Addult and Children's Leukemia Working Parties. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001; 98: 1312–1320.

    Article  CAS  PubMed  Google Scholar 

  15. Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W, Haferlach T . The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 2004; 89: 1082–1090.

    PubMed  Google Scholar 

  16. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al., for the SWOG and ECOG. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075–4083.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all clinicians for sending AML samples to our laboratory for diagnostic purposes.

Author information

Authors and Affiliations

  1. MLL Munich Leukemia Laboratory, Max-Lebsche-Platz, Munich, Germany

    C Haferlach, F Dicker, H Herholz, S Schnittger, W Kern & T Haferlach

Authors
  1. C Haferlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Dicker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Herholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Schnittger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Haferlach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Haferlach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haferlach, C., Dicker, F., Herholz, H. et al. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 22, 1539–1541 (2008). https://doi.org/10.1038/leu.2008.143

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.143

Keywords

This article is cited by

Search

Advanced search

Quick links